Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
|
29916268 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
GPC3 immunostaining was positive in all HCCs and negative in dysplastic nodules (22/22 vs 0/14, respectively, P < .001).
|
17087938 |
2006 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The identified genes, such as GPC3 that are distinctly expressed in liver CD90(+)CSCs, may be promising gene candidates for HCC therapy without inducing damages to normal liver stem cells.
|
22606345 |
2012 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, miR-4510 inversely correlated with GPC3 mRNA and protein in HCC samples.
|
28476031 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although the precise function of GPC3 remains unclear, it has been strongly suggested that it is related to the malignant transformation of HCC.
|
31024850 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC).
|
29508107 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, GPC3 is associated with the HCC cell biological behavior, while the relationship between GPC3 and EMT in tumorigenesis of HCC deserves future investigation.
|
25270552 |
2014 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RNAscope for GPC3 and GS panel was highly specific and sensitive for the pathological identification of dysplastic nodules, early stages of HCCs, and would differentiate them from HCCs and metastatic tumors compared with IHC.
|
31832976 |
2020 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
It also was demonstrated that GPC3CAR-T cells displayed potent cytotoxicity against GPC3-positive HCC cell lines in vitro by using real-time cell analyser (RTCA) system and the JuLI™ Stage Cell History Recorder.
|
31522780 |
2020 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
As the early warning biomarker, 3 or more anti-URGs were served as the threshold to separate the cirrhosis and HCC from others with a moderate sensitivity (58.3%) and specificity (80.0%), which was better than other biomarkers (AFP, AFP-L3, GPC3 and GP73) and would improve up to 70.3% when combined with another biomarker.
|
22820138 |
2012 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the current knowledge regarding the structure, function, and biology of GPC3 with a focus on its clinical potential as a diagnostic molecule and a therapeutic target in HCC immunotherapy.
|
28621802 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
|
25320357 |
2014 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Positive glypican-3 staining was found in 70% of HCCs and negative staining was seen in all non-tumor areas.
|
24369267 |
2014 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Glypican 3 (GPC3) is a valuable diagnostic marker and a potential therapeutic target in hepatocellular carcinoma (HCC).
|
25625609 |
2015 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments.
|
30275801 |
2018 |
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We report here that a mutant GPC3 that cannot be processed by convertases is still able to play its stimulatory role in Wnt activity and HCC growth.
|
16227623 |
2005 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Collectively, these results suggest that progression of hepatocellular carcinoma is associated with upregulation of GPC3.
|
16682817 |
2006 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
We report here that a mutant GPC3 that cannot be processed by convertases is still able to play its stimulatory role in Wnt activity and HCC growth.
|
16227623 |
2005 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Glypican-3 (GPC3) is a new reliable HCC marker, which is involved in tumor growth in HCC, primarily mediated by wnt/β-catenin signaling.
|
29379301 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We reported recently the novel tumor marker glypican-3 (GPC3) for hepatocellular carcinoma.
|
15475451 |
2004 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Specific shRNA might intervene effectively GPC-3 activation and inhibit tumor cell proliferation, suggesting that GPC-3 gene should be a potential molecular target for HCC therapy.
|
23192642 |
2013 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy.
|
30922327 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Targeting of hepatocellular carcinoma with glypican-3-targeting peptide ligand.
|
21976137 |
2011 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Collectively, these results suggest that progression of hepatocellular carcinoma is associated with upregulation of GPC3.
|
16682817 |
2006 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These analyses were performed by comparing the expression of PTGR1 to that of two well-known markers of hepatocarcinoma, Glutathione S-transferase pi 1 (GSTP1) in rats and glypican-3 in humans.
|
24853774 |
2014 |